COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE)

Bull Cancer. 2021 May;108(5):490-500. doi: 10.1016/j.bulcan.2021.02.004. Epub 2021 Mar 11.

Abstract

Since the emergence of the SARS-CoV-2 infection, many recommendations have been made. However, the very specific nature of acute lymphoblastic leukemias and their treatment in children and adolescents led the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE) to propose more specific recommendations. Here is the second version of these recommendations updated according to the evolution of knowledge on COVID19.

Keywords: Acute lymphoblastic leukemia; Adolescents; COVID 19; Children; SARS-CoV-2.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Adenosine Monophosphate / therapeutic use
  • Adolescent
  • Adrenal Cortex Hormones / therapeutic use
  • Alanine / analogs & derivatives
  • Alanine / therapeutic use
  • Antiviral Agents / therapeutic use
  • COVID-19 / diagnosis
  • COVID-19 / epidemiology*
  • COVID-19 Drug Treatment
  • COVID-19 Nucleic Acid Testing
  • COVID-19 Vaccines / therapeutic use
  • Cancer Care Facilities
  • Child
  • Consolidation Chemotherapy
  • Drug Interactions
  • France / epidemiology
  • Humans
  • Induction Chemotherapy / methods
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Maintenance Chemotherapy / methods
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Recurrence
  • Risk Assessment
  • Societies, Medical

Substances

  • Adrenal Cortex Hormones
  • Antiviral Agents
  • COVID-19 Vaccines
  • remdesivir
  • Adenosine Monophosphate
  • Alanine